|
WO2010064126A2
|
|
Controlled release dosage forms
|
|
WO2010015692A2
|
|
Bupropion hydrobromide polymorphs
|
|
WO2010015567A2
|
|
Controlled release formulations using intelligent polymers
|
|
US2011052684A1
|
|
Pharmaceutical composition
|
|
EP2233140A1
|
|
Bicyclic amides for enhancing glutamatergic synaptic responses
|
|
US2010203128A1
|
|
Bupropion hydrobromide and therapeutic applications
|
|
EP2074993A1
|
|
Venlafaxine-containing film-coated modified-release tablets
|
|
CA2612999A1
|
|
Modified release composition of at least one form of venlafaxine
|
|
US2008175873A1
|
|
Modified release composition of at least one form of venlafaxine
|
|
US2008138404A1
|
|
Extended release formulations of carvedilol
|
|
US2008274181A1
|
|
Bupropion hydrobromide and therapeutic applications
|
|
US2008075774A1
|
|
Bupropion hydrobromide and therapeutic applications
|
|
EP2032124A1
|
|
Multiparticulate osmotic delivery system
|
|
US2009004281A1
|
|
Multiparticulate osmotic delivery system
|
|
WO2007078895A2
|
|
Modified release formulations of tramadol and uses thereof
|
|
ZA200711123B
|
|
Modified-release formulations of a bupropion salt
|
|
KR20080013927A
|
|
Modified-release composition of at least one form of venlafaxine
|
|
US2006153914A1
|
|
Chronotherapeutic diltiazem formulations and the administration thereof
|
|
CA2510119A1
|
|
Modified-release composition of at least one form of venlafaxine
|
|
CA2509124A1
|
|
Modified-release composition of at least one form of venlafaxine
|
